Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes
GPR120 is a promising target for the treatment of type 2 diabetes (T2DM), which is activated by free fatty acids (FFAs) and stimulates the release of glucagon-like peptide-1(GLP-1). GLP-1, as an incretin, can enhance glucose-dependent secretion of insulin from pancreatic beta cells and reduce blood...
Main Authors: | Guoxia Ji, Qinghua Guo, Qidi Xue, Ruifang Kong, Shiben Wang, Kang Lei, Renmin Liu, Xuekun Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/22/6907 |
Similar Items
-
Discovery of Novel and Selective G-Protein Coupled Receptor 120 (GPR120) Agonists for the Treatment of Type 2 Diabetes Mellitus
by: Xuekun Wang, et al.
Published: (2022-12-01) -
Polyunsaturated fatty acid receptors, GPR40 and GPR120, are expressed in the hypothalamus and control energy homeostasis and inflammation
by: Nathalia R. V. Dragano, et al.
Published: (2017-04-01) -
Regulation of energy homeostasis via GPR120
by: Atsuhiko eIchimura, et al.
Published: (2014-07-01) -
Fluorescent Ligand-Based Discovery of Small-Molecule Sulfonamide Agonists for GPR120
by: Siyue Ma, et al.
Published: (2022-01-01) -
The GPR120 agonist TUG‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat
by: Maaike Schilperoort, et al.
Published: (2018-03-01)